VistaGen Therapeutics, Inc.

NasdaqCM:VTGN Stock Report

Mkt Cap: US$51.6m

We’ve recently updated our valuation analysis.

VistaGen Therapeutics Valuation

Is VTGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTGN?

Other financial metrics that can be useful for relative valuation.

VTGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue-107.1x
Enterprise Value/EBITDA-0.3x
PEG Ration/a

Price to Book Ratio vs Peers

How does VTGN's PB Ratio compare to its peers?

The above table shows the PB ratio for VTGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.7x
SLS SELLAS Life Sciences Group
BCDA BioCardia
ADVM Adverum Biotechnologies
ORTX Orchard Therapeutics
VTGN VistaGen Therapeutics

Price to Earnings Ratio vs Industry

How does VTGN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.7%

Price to Book Ratio vs Fair Ratio

What is VTGN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTGN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VTGN's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of VTGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Discover undervalued companies